relapsing-remitting

In other news, Novartis's new analysis of its multiple sclerosis drug Gilenya showed the pill lowered the risk of the disease getting worse in patients with relapsing-remitting MS, regardless of treatment history.

Novartis Cancels Cancer Drug Anita Greil 2011

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended that the orally taken drug be used in Europe at a 0.5-milligram daily dose to treat patients with highly active relapsing-remitting multiple sclerosis.

Novartis Wins European Backing for MS Pill Goran Mijuk 2011

It said it was unclear how much the drug would help the specific group of people for whom it was licensed – adults with relapsing-remitting multiple sclerosis RRMS who experienced at least one relapse a year despite being treated with beta interferon drugs.

MS Society calls for rethink after first pill treatment is rejected 2011

Gilenya has been available in the European Union since March 2011 for treating relapsing-remitting MS, the most common type of the disease, in patients who have failed to respond to a beta-interferon or whose condition is severe and worsening rapidly.

EU Regulator Reviews Novartis MS Pill Sten Stovall 2012

Gilenya's approval was partly expected after the European Medicines Agency's Committee for Medicinal Products for Human Use earlier this year recommended the orally taken drug be used at a 0.5-milligram daily dose for patients with a highly active relapsing-remitting multiple sclerosis.

Novartis's MS Drug Gets Approval from EU Goran Mijuk 2011

Merck KGaA shed 2.8% after the German drug maker said it no longer will pursue global approval of its Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.

Europe's Markets Fall Andrea Tryphonides 2011

The U.K.'s National Institute for Health and Clinical Excellence, or NICE, while acknowledging that trial data showed that Gilenya benefits patients with highly active relapsing-remitting multiple sclerosis, said it was unclear how much the drug may help patients with other relapse forms.

Corporate Watch 2011

The daclizumab study followed 600 patients with relapsing-remitting multiple sclerosis, the most common form of the condition, over one year.

Biogen, Abbott MS Drug Shows Effectiveness Thomas Gryta 2011

The U.K.'s National Institute for Health and Clinical Excellence, or NICE, while acknowledging that trial data showed that Gilenya benefits patients with highly active relapsing-remitting multiple sclerosis, said it was unclear how much the drug may help patients with other relapse forms.

Novartis' MS Pill Questioned by U.K. Regulator Goran Mijuk 2011

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the orally taken drug be used in Europe at a 0.5-milligram daily dose to treat patients with highly active relapsing-remitting multiple sclerosis.

Business Watch 2011